Post

Back to All Publications

Topics

Recommended For You

Too Much Equipment, Not Enough Room: Rethinking Capital Efficiency in Cell Processing

When cell therapy developers think about efficiency, the conversation usually centers on yield, throughput, or cost of goods. But in nearly every cleanroom we walk into, the most pressing constraint isn’t reagents or labor—it’s physical space. With limited room for equipment, teams are forced to make trade-offs: Can we get by with what we have? What else can this system do? The real question becomes how to maximize what you already have without sacrificing flexibility or performance. In this piece, we explore how capital efficiency in cell processing comes from smarter equipment choices, not just buying less. That means choosing systems that adapt to shifting workflows, support multiple unit operations, and make the most of every square foot. Based on what we’re hearing from the field, it’s time to rethink how equipment is deployed—not as fixed-function tools, but as adaptable assets that work harder for the footprint they occupy.

Article
From Culture to Cryo: Smarter Cell Washing and Pre-Formulation for Allogeneic Therapies

In allogeneic cell therapy manufacturing, cell washing and pre-formulation mark the final point of control before cells are filled, frozen, and shipped – whether processing iPSCs, MSCs, NK cells, CAR-T cells, or other donor-derived immune cell types. These steps must efficiently remove residual media, preserve viability, and prepare the product for storage or clinical use—without compromising quality or consistency. Yet many workflows still rely on open systems, manual handling, or separation methods not optimized for sensitive cell types. The result is often variable recovery, inconsistent buffer exchange, and a higher risk of contamination. Cell washing and pre-formulation aren’t just end-of-line steps—they’re essential to ensuring the integrity of the final product.

Article
Rethinking Cell Harvesting: A Strategic Lever in Allogeneic Therapy Production

In allogeneic therapies, harvested cells are the final product—or a critical intermediate—making gentle cell separation and recovery essential to overall process performance. Losses at this stage can compromise potency, reduce yield, and introduce variability that can carry through to downstream operations. Protecting cell health while achieving high recovery is essential, especially as production scales and regulatory expectations intensify. In this context, cell harvesting is not just a technical step but a strategic opportunity to improve product quality, process reliability, and overall manufacturing success.

Article

Stay Connected

Contact Us

Get in touch with a sales representative, request support or download our free white paper.

Topics

Recommended For You

Too Much Equipment, Not Enough Room: Rethinking Capital Efficiency in Cell Processing

From Culture to Cryo: Smarter Cell Washing and Pre-Formulation for Allogeneic Therapies

Rethinking Cell Harvesting: A Strategic Lever in Allogeneic Therapy Production

Stay Connected

Contact Us

Subscribe for Email Updates